EGM
ADAP

Engineers Gate Manager’s Adaptimmune Therapeutics ADAP Stock Holding History

Engineers Gate Manager’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-14,294
Closed -$24K – 1564
2022
Q2 		$24K Buy
+14,294
New +$24.6K ﹤0.01% 1817
2021
Q2 		– Sell
-39,100
Closed -$208K – 1562
2021
Q1 		$208K Buy
+39,100
New +$224K 0.01% 1578

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Engineers Gate Manager's ADAP Position: Q3 2022 in Review

Engineers Gate Manager sold out of Adaptimmune Therapeutics (ADAP) in Q3 2022, closing a stake of 14,294 shares — an estimated $24K sold.

Engineers Gate Manager first reported a position in ADAP in Q1 2021 and held it in 2 quarters. The position peaked at $208K in Q1 2021. 68 funds tracked by Wall St. Rank hold ADAP as of Q3 2022.

  • Engineers Gate Manager reported no remaining Adaptimmune Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Engineers Gate Manager sold 14,294 Adaptimmune Therapeutics shares in Q3 2022, an estimated $24K.
  • Engineers Gate Manager first reported a position in Adaptimmune Therapeutics in Q1 2021 and held it in 2 quarters.
  • Engineers Gate Manager's Adaptimmune Therapeutics position peaked at $208K in Q1 2021.
  • 68 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2022.

Based on Engineers Gate Manager's 13F filing for Q3 2022, filed 14 Nov 2022.